In April 2024, the Alabama Board of Examiners in Counseling issued a policy statement that has not received the attention it deserves. The statement addresses the question of whether a licensed professional counselor or associate licensed counselor in Alabama may participate in Ketamine-Assisted Therapy, the increasingly popular pairing of sub-anesthetic ketamine administration with concurrent psychotherapeutic processing. The Board’s answer was unequivocal. Any situation in which ketamine is advised, administered, or actively used during a psychotherapeutic intervention in a counseling setting, without a licensed physician physically present, falls outside the protected scope of professional counseling in this state. The Board further stated that complaints alleging such conduct would not be handled internally by its ethics committee but would be forwarded directly to the Alabama Board of Medical Examiners for investigation as potential unauthorized practice of medicine.

Under Code of Alabama §§ 34-24-50 and 34-24-51, the unauthorized practice of medicine in Alabama is a Class C felony. The statutory definition of practicing medicine is broad enough to reach any attempt to diagnose, treat, correct, advise, or prescribe for any human disease, ailment, or mental condition by any instrumentality. A counselor who participates substantively in a ketamine session in this state, in other words, is not facing a board sanction. They are facing a referral to a different board with the power to recommend criminal prosecution. The licensing risk is real but secondary. The primary risk is criminal.

I am writing this article because I have had three conversations in the past year, with clinicians I respect, who did not appear to understand this. Two were considering offering KAT in collaboration with online prescribers. One was already accepting referrals from a ketamine clinic and was unsure how much processing they could legally do during the infusion versus after it. The information environment around psychedelic-assisted therapy is dominated by national thought leaders writing from California, Oregon, and Colorado, where the legal landscape is dramatically different from ours. Alabama clinicians who absorb that material without translating it for local statute are putting their careers and their freedom at risk without knowing it.

The usual disclaimer applies. I am a clinical social worker, not an attorney. This article is policy commentary intended to make a regulatory landscape visible. Practitioners with specific questions about KAT participation, collaborative practice structures, integration work, or scope-of-practice exposure in Alabama should consult an attorney experienced in administrative and medical regulatory law before relying on anything in this piece. The cost of a consultation is trivial compared to the cost of being wrong.

What the ALBME Says Ketamine Actually Is

The medical board’s framing of ketamine matters because it determines the operational standard of care. The Alabama Board of Medical Examiners treats off-label ketamine for treatment-resistant depression as the practice of medicine, full stop. The clinical reasoning is straightforward. Ketamine is a dissociative anesthetic with serious physiological risk profile. The drug can produce sharp blood pressure elevations, respiratory depression, cardiac events, and seizures. These are not theoretical risks. They are the reasons the drug requires anesthesia training to use in surgical contexts. The ALBME’s position is that the same drug used at lower doses for psychiatric purposes is still capable of producing the same adverse events, and therefore the standard of care must include the same level of medical readiness.

The ALBME’s published expectations for outpatient ketamine administration include, at minimum, a comprehensive physical examination by the physician before administration, a history of previous antidepressant trials, a urine toxicology screen to identify contraindicating substances, specialized informed consent that explicitly addresses the off-label nature of the application, immediate emergency response capability on premises during the infusion, and a hard rule that infusions are discontinued the moment respiratory distress or cardiac involvement appears. Patients cannot drive home and cannot be released to family for monitoring. Home administration for psychiatric purposes is prohibited. Infusions are capped at twice weekly to limit cumulative toxicity and dependence.

Read together, these requirements describe a medical procedure that cannot be safely conducted inside a typical outpatient counseling office. The infrastructure is wrong, the training is wrong, the regulatory category is wrong. The counselor’s office is the place where the patient can show up after the medical event has occurred, not the place where the medical event can occur. This is the structural fact underneath the ABEC ruling, and it does not change because the dose is low, because the patient seems stable, because the prescribing physician is somewhere accessible by video, or because the substance is being self-administered at home under prescription. Each of those framings has been tried in other states, with results ranging from regulatory action to criminal charges to fatalities.

The Two Activities the Statute Distinguishes

The legal landscape becomes much clearer once one separates two activities that often get conflated under the heading of “psychedelic therapy.” The first activity is the active administration phase, in which the patient is under the acute physiological influence of the substance. The second activity is integration, in which the patient is fully sober and is psychotherapeutically processing the material that came up during a prior, separately conducted medical session.

Active administration in Alabama is medicine. It must be conducted by a physician or under the direct, physically present supervision of a physician who is assuming legal responsibility for the medical event. A counselor or clinical social worker who is present in the room during active administration is not engaging in counseling. They are participating in a medical procedure, and the only legal posture in which they can do so is as an adjunct provider operating inside a formal medical practice structure in which a physician carries primary liability. This typically means an employment agreement or a formally constituted collaborative practice in which the physician’s name appears on the medical record as the responsible party, the clinic operates under appropriate medical licensure, and the therapist’s role is limited to providing psychological support within the medical event rather than directing it.

Integration, by contrast, is psychotherapy. A counselor or clinical social worker who provides standard, substance-free psychotherapy to a patient who has independently received ketamine treatment at a separate, licensed medical facility is operating squarely within their scope. The work is recognizable as therapy. It uses the same tools the clinician already uses for any depth-oriented case, namely the patient’s recall, affect, association, dream content, somatic experience, and meaning-making, applied to material that surfaced in a particular state of consciousness. There is no controlled substance in the room. There is no medical monitoring. There is no prescribing. The therapist did not advise on dosage. The therapist did not arrange the medical encounter. The therapist did not bill for the medical encounter. The therapist is doing what therapists have always done with material from elsewhere, which is help the patient make use of it.

The legal cliff lives between these two activities, and the cliff is steep. The counselor who advises a patient on what dose to ask their prescriber for, who is on video during a home ketamine self-administration session “for support,” who tracks vital signs during an in-office session, who recommends a particular ketamine clinic in exchange for referrals, or who allows their office to be used as a site for ketamine administration with a physician participating remotely, is on the wrong side of that cliff in Alabama. Each of those activities can be characterized as advising, treating, or monitoring within the meaning of the medical practice statute. The fact that the counselor’s intent was therapeutic does not change the legal characterization. Intent is not an element of the unauthorized practice statute.

Why “Collaborative Practice” Is Not a Loophole

The phrase “collaborative practice” gets used loosely in psychedelic therapy circles in ways that obscure how high a bar it actually is in Alabama. Collaborative practice in the ALBME’s understanding is not a referral relationship, an MOU, a shared client, or a shared office space. It is a formal practice structure in which a physician carries primary clinical and legal responsibility for the medical aspects of patient care and the non-physician clinicians work as adjunct providers within that physician’s medical practice.

This generally means, at minimum, that the medical practice is operating under appropriate medical licensure, that the physician is enrolled with the insurance and DEA registrations required to prescribe and administer the substance, that the medical record is maintained by the physician’s practice, that the physician conducts the pre-administration evaluation and is physically present and responsible during administration, that the practice’s liability insurance covers the medical procedure, and that the therapist’s adjunctive role is documented in writing as part of the medical practice’s protocols rather than as a freestanding therapy service.

The practical implication for an outpatient therapy office is that you cannot bolt KAT onto an existing counseling practice and remain compliant. You would need to fundamentally restructure the business as a medical practice, partner with a physician who is willing to carry that liability, secure the appropriate licensing and insurance for medical procedures, and accept that the therapy work conducted within the KAT context is operating under a different liability and billing structure than the rest of your caseload. Most outpatient practices do not have the capital, the physician partnerships, or the appetite for medical liability to make this work. Which is precisely why the safer model for most clinicians is integration alone.

What Integration Work Looks Like When You Do It Cleanly

Integration is good clinical work, and the legal safety of doing only integration should not be confused with a lesser form of practice. Some of the most useful therapeutic material I have seen in my own caseload over the last several years has emerged from integration work with patients who received ketamine infusions or generic NMDA-antagonist treatments through separate medical providers and brought what surfaced back into the consulting room.

The structural requirements for keeping that work clean in Alabama are not complicated. The patient initiates the medical encounter independently, through a physician’s office that conducts its own evaluation, administers the substance on its own premises under its own protocols, and bills for its own services. You do not refer in a way that creates the appearance of a clinical handoff into a procedure you have planned for the patient. You do not coordinate the timing of the infusion with the timing of the integration session in ways that suggest the two are pieces of a single treatment plan you are directing. Your documentation reflects what it actually is, which is psychotherapy with a patient who happens to be receiving treatment from a separate medical provider, much as you might work with a patient whose psychiatrist has them on lamotrigine.

The integration session itself uses whatever modality you would otherwise use. For my own practice, that means Brainspotting, Lifespan Integration, somatic work, and depth-oriented processing, depending on what the patient brings and what their nervous system can hold. The presence of psychedelic material does not require psychedelic-branded technique. The patient’s experience is the data. The work is making meaning of the data without overlaying interpretations that belong to the prescriber, to the wellness industry, or to your own enthusiasm about the modality. This last point is where many integration practitioners drift, particularly those who came to integration work because they were excited about psychedelics in general. The patient’s session belongs to the patient, not to the modality.

Where the Risk Currently Concentrates

The clinicians at highest risk in Alabama right now are the ones who are receiving referrals from out-of-state telehealth ketamine prescribers. The structure of those referrals tends to be that the prescriber dispenses ketamine lozenges to the patient with instructions for at-home self-administration, the patient is told to schedule a “ketamine-assisted therapy” session with a local therapist for the administration window, and the therapist is invited to be present, often by video, “to support the experience.”

From the patient’s vantage point, this looks like a coherent treatment plan. From the legal vantage point in Alabama, the therapist in that scenario is participating in the administration of a controlled substance outside of a medical practice, often without the physical presence of any medical provider, in violation of both the ABEC ruling and the ALBME’s standards for ketamine administration. Whether or not the prescriber’s home state permits this model is irrelevant to whether the therapist in Alabama is in legal jeopardy. The therapist’s conduct is being judged under Alabama law, in Alabama, regardless of where the prescriber sits.

I have seen marketing materials from several national platforms that present this structure as compliant on the basis of the prescriber’s licensure in some other state. The marketing materials are not legal opinions, and the Alabama Board of Medical Examiners has not opined that out-of-state prescribing creates a safe harbor for in-state therapist participation. If you are receiving solicitations from these platforms, the prudent move is not to evaluate them on the basis of how well-credentialed the prescriber appears. The prudent move is to ask, in writing, what their counsel has advised regarding therapist participation in jurisdictions like Alabama, and to obtain your own independent counsel before participating.

The Broader Picture

The ABEC and ALBME rulings on ketamine should be understood as the first wave of a regulatory posture that will likely extend to whatever psychedelic and dissociative modalities reach the outpatient market next. The state’s medical board has historically held a conservative position on the relationship between substance administration and psychotherapeutic context. There is no indication that the posture is loosening. The most likely trajectory is that as psilocybin services, MDMA-assisted therapy, and other psychedelic modalities continue to develop in jurisdictions like Oregon and Colorado, Alabama will respond by reiterating the same boundary. Therapists may engage psychologically with material from these modalities. Therapists may not administer, monitor, or participate in the active pharmacological phase outside of a formal medical practice structure.

For depth-oriented clinicians who are genuinely curious about how altered states can serve trauma work, this is not the end of the road. There is significant clinical territory in non-pharmacological altered-state work that is fully within scope in Alabama. Brainspotting accesses a different register of consciousness than ordinary talk therapy and is doing so within recognized scope. Lifespan Integration works with state-shifts across the timeline of memory. Somatic Experiencing engages the autonomic nervous system in ways that produce significant non-ordinary phenomenology. None of these modalities require a controlled substance, and none of them carry the criminal exposure that KAT carries in this state. The clinician who wants to work at the edge of consciousness in Alabama is not blocked from doing so. They are blocked from doing so with a Schedule III drug in the room, and the reasons for that block are not arbitrary. They reflect a serious legislative and regulatory judgment about who is responsible when something goes wrong physiologically, and the answer in Alabama is a physician, not a counselor.

The shorter version of this entire article, the one I would say to a colleague over coffee, is this. Integration is yours. Administration is medicine. If a referral structure blurs that line, it is your career and possibly your freedom at stake, and the fact that someone has built a national business model around blurring it does not transfer the risk away from you. Get the question in front of a lawyer before you get the patient in front of a substance. The rest is doing the work you were trained to do, which is more than enough.

Joel Blackstock is an LICSW-S and Clinical Director of Taproot Therapy Collective in Birmingham, Alabama, where the practice specializes in complex trauma and depth psychotherapy, including Brainspotting, Lifespan Integration, and Somatic Experiencing. This article is policy commentary from a clinical perspective and is not legal advice. Practitioners with specific questions about scope of practice, collaborative practice structures, or psychedelic integration work in Alabama should consult an attorney experienced in Alabama administrative and medical regulatory law before relying on anything in this article.